Skip Navigation LinksHome > May 2013 - Volume 28 - Issue 3 > Clopidogrel and warfarin pharmacogenetic tests: what is the...
Current Opinion in Cardiology:
doi: 10.1097/HCO.0b013e32835f0bbc
MOLECULAR GENETICS: Edited by Ali J. Marian

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Shahin, Mohamed H.A.; Johnson, Julie A.

Supplemental Author Material
Collapse Box


Purpose of review: To review the most promising genetic markers associated with the variability in the safety or efficacy of warfarin and clopidogrel and highlight the verification and validation initiatives for translating clopidogrel and warfarin pharmacogenetic tests to clinical practice.

Recent findings: Rapid advances in pharmacogenetics, continuous decrease in genotyping cost, development of point-of-care devices and the newly established clinical genotyping programs at several institutions hold the promise of individualizing clopidogrel and warfarin based on genotype. Guidelines have been established to assist clinicians in prescribing clopidogrel or warfarin dose based on genotype. However, the clinical utility of clopidogrel and warfarin is still limited. Accordingly, large randomized clinical trials are underway to define the role of clopidogrel and warfarin pharmacogenetics in clinical practice.

Summary: Pharmacogenetics has offered compelling evidence toward the individualization of clopidogrel and warfarin therapies. The rapid advances in technology make the clinical implementation of clopidogrel and warfarin pharmacogenetics possible. The clinical genotyping programs and the ongoing clinical trials will help in overcoming some of the barriers facing the clinical implementation of clopidogrel and warfarin pharmacogenetics.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.